News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

March 4, 2021 Apellis Provides Update on APL-9 for Severe COVID-19
February 25, 2021 Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
February 22, 2021 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
February 18, 2021 Apellis Pharmaceuticals to Hold Fourth Quarter and Full Year 2020 Earnings Conference Call on February 25, 2021
January 26, 2021 Apellis Announces Closing of Previously Announced Exchanges of Approximately $126.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
January 21, 2021 Apellis Pharmaceuticals to Host Investor Event on Geographic Atrophy on January 28, 2021
January 7, 2021 Apellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
January 5, 2021 Apellis Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
December 10, 2020 Apellis and Sobi Report Positive Top-line Results at 48 Weeks from the Phase 3 PEGASUS Study of Pegcetacoplan in PNH
December 7, 2020 Apellis Reports Pegcetacoplan Demonstrates Greater Treatment Responses and Quality-of-Life Improvements Compared to C5 Inhibitors for PNH